Core Insights - Medicenna Therapeutics Corp. announced promising preclinical data for its novel immunotherapy MDNA113, which targets IL-13Rα2 and shows potential for treating a wide range of malignancies, including "cold tumors" affecting over two million patients annually [1][6] - The company will present updated clinical results from the MDNA11 Phase 1/2 ABILITY-1 study at the 39th Annual Meeting of SITC [1][2] Group 1: MDNA113 Overview - MDNA113 is a novel IL-13Rα2 tumor-targeted BiSKIT designed to deliver an anti-PD1-IL-2 Superkine to the tumor microenvironment, activated by tumor-associated proteases [1][6] - Treatment with MDNA113 resulted in complete tumor regression in IL-13Rα2 expressing tumors, indicating its effectiveness in aggressive cancer models [2][3] - The drug demonstrated the ability to prevent metastasis in a triple-negative breast cancer model when administered prior to surgery, achieving 100% survival [3][4] Group 2: Preclinical and Clinical Data - Preclinical studies showed that MDNA113 significantly inhibited tumor growth in IL-13Rα2 positive tumors and improved tolerability compared to unmasked anti-PD1-IL-2SK [3][4] - Independent research indicated that MDNA11 and anti-PD1-IL-2SK BiSKIT extended overall survival in aggressive glioblastoma mouse models and stimulated immune cell activity in human GBM explants [2][4] - Ex-vivo studies with patient-derived GBM explants treated with IL-2SK or anti-PD1-IL-2SK showed increased CD8+ T and NK cell populations alongside reduced tumor burden [5] Group 3: Medicenna's Technology Platforms - MDNA113 is based on Medicenna's IL-2 and IL-13 Superkine platforms, with MDNA11 being a long-acting IL-2 super agonist currently in clinical evaluation [2][7] - MDNA11 is engineered to preferentially activate immune effector cells while minimizing stimulation of immunosuppressive Tregs, enhancing its therapeutic potential [7][8] - Medicenna focuses on developing highly selective versions of Superkines to address unmet needs in oncology, with ongoing studies for various cancer types [8]

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. AK132 is an asymmetric bispecific antibody with a "1+1" valency, designed to simultaneously target and block CLDN18.2 and CD47. It features a wild-type IgG1 Fc struct ...

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural’s IL-18 variants, reinforcing pursuit of IND-enabling studies with candidate nomination anticipated by the end of 2024, and IND submission expected in Q4 2025 Additional preclinical data from Mural’s IL-12 pro ...

Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival (“DFS”) and T cell response ELI-002 Phase 1 safety and tolerability profile remains favorable ELI-002 Phase 2 interim event-driven DFS analysis expected in H1 2025 BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechn ...

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Presenting new clinical data from Phio's on-going Phase 1b trialNovember 07, 2024 10:00 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene sile ...

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneerin ...

Core Insights - Indaptus Therapeutics presented promising safety, pharmacokinetics, and biomarker data for its lead compound Decoy20 at the SITC 2024 annual meeting, based on a Phase 1 clinical trial involving 19 patients [1][2][3] - The trial results indicated that Decoy20, administered intravenously once weekly, primarily resulted in mild to moderate and transient side effects, with a rapid elimination from the bloodstream supporting the company's "pulse" approach [2][3] - One patient with squamous cell carcinoma of the head and neck exhibited "stable disease" at the first imaging scan, indicating no progression of cancer [2] Company Overview - Indaptus Therapeutics focuses on innovative cancer and viral infection treatments, leveraging a patented Decoy platform that activates both innate and adaptive immune responses [4] - The Decoy technology utilizes non-pathogenic Gram-negative bacteria to stimulate immune pathways, aiming for reduced intravenous toxicity while maintaining efficacy [4] - Preclinical studies have shown Decoy candidates' effectiveness against various cancers and chronic viral infections, demonstrating potential for combination therapies with existing treatments [4] Future Directions - The company is expanding its clinical trial to include patients with six different tumor types for weekly dosing and is collaborating with BeiGene to combine Decoy20 with its PD-1 inhibitor, tislelizumab [3] - Management expresses confidence in the Decoy platform's potential and plans to continue sharing positive results while exploring new opportunities [3]

Core Insights - Oncotelic Therapeutics, Inc. presented its research at SITC 2024, focusing on the TGFB2 therapeutics pipeline [1] - Dr. Cynthia Lee, VP of R&D, has been instrumental in leading R&D programs and the establishment of a GMP facility in San Diego [1] Research Presentations - Abstract Number 198 discusses the interaction of TGFB2 mRNA levels with Interferon-alpha receptor activation and its impact on overall survival in pancreatic ductal adenocarcinoma (PDAC) [1] - Abstract Number 218 evaluates the prognostic impact of TGFB2 mRNA levels in low-grade gliomas, in conjunction with Interferon-gamma receptor activation [1] - Abstract Number 1444 presents a meta-analysis comparing serious adverse events and survival outcomes in PDAC patients treated with mFOLFIRINOX or FOLFIRINOX [1] Company Overview - Oncotelic has a rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture, GMP Biotechnology Limited, and is involved in treatments for melanoma and Acute Myeloid Leukemia [2] - The company acquired PointR Data Inc. in November 2019 to enhance its AI-driven biotechnology capabilities [2] - Oncotelic is developing AL-101 for various conditions, including Parkinson's Disease and sexual disorders, addressing a significant patient population [2] - The first-in-class TGFB2 therapeutic for pancreatic cancer and glioblastoma is being developed through its joint venture, Sapu Bio [2]

Core Insights - Anixa Biosciences, Inc. is set to present additional data from its Phase 1 clinical trial of a breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting on November 8, 2024 [1][2] - The vaccine targets the α-lactalbumin protein, which is present in certain breast cancers but absent in normal aging tissues post-lactation, aiming to activate the immune system for preemptive protection against breast tumors [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program and various cancer vaccines developed in collaboration with Cleveland Clinic [7] - The breast cancer vaccine technology was developed by Dr. Vincent Tuohy at Cleveland Clinic, and Anixa holds the exclusive worldwide license for this technology [5][6] Clinical Trial Details - The Phase 1 trial is conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense, with initial data showing no safety concerns and immune responses in a majority of patients [4][5] - The upcoming presentation will provide further analysis of the trial data, which was initially presented at the San Antonio Breast Cancer Symposium in December 2023 [4][2]

MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pion ...